NASDAQ
11.39USD
+0.64 (+5.95%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
616.6M
P/E
—
EPS
—
Beta
0.86
52W range
7.9-17.4
Day range
10.75–12.11
Open
10.87
Prev close
10.75
Volume
532K
Avg volume
369.9K
Dividend
0.00
IPO
2026-02-05
https://seekingalpha.com/article/4939273-eikon-therapeutics-inc-eikn-discusses-advances-in-parp1-biology-and-next-generation-parp · 8/22/2026+0.60
https://www.benzinga.com/markets/market-summary/26/07/60702801/crude-oil-falls-sharply-us-durable-goods-orders-increase-0-3-in-june · 7/27/2026+1.00
https://www.globenewswire.com/news-release/2026/05/30/3303899/0/en/Eikon-Therapeutics-Presents-Data-on-Clinical-Stage-Programs-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html · 5/30/2026+0.80
https://www.globenewswire.com/news-release/2026/05/11/3292291/0/en/Eikon-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Clinical-Updates.html · 5/11/2026+0.30
https://www.reuters.com/business/healthcare-pharmaceuticals/perlmutter-backed-eikon-therapeutics-raises-3812-million-ipo-2026-02-05/ · 2/5/2026+0.80
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
